18 results on '"Sukhin, Vladyslav"'
Number of results to display per page
Search Results
2. SUCCOR morbidity: complications in minimally invasive versus open radical hysterectomy in early cervical cancer
- Author
-
Vázquez-Vicente, Daniel, Boria, Felix, Castellanos, Teresa, Gutierrez, Monica, Chacon, Enrique, Manzour, Nabil, Minguez, Jose Angel, Martin-Calvo, Nerea, Alcazar, Juan Luis, Chiva, Luis, Zanagnolo, Vanna, Querleu, Denis, Arévalo-Serrano, Juan, Căpîlna, Mihai Emil, Fagotti, Anna, Kucukmetin, Ali, Mom, Constantijne, Chakalova, Galina, Aliyev, Shamistan, Malzoni, Mario, Narducci, Fabrice, Arencibia, Octavio, Raspagliesi, Francesco, Toptas, Tayfun, Cibula, David, Kaidarova, Dilyara, Meydanli, Mehmet Mutlu, Tavares, Mariana, Golub, Dmytro, Perrone, Anna Myriam, Poka, Robert, Tsolakidis, Dimitrios, Vujić, Goran, Jedryka, Marcin A, Zusterzeel, Petra L M, Beltman, Jogchum Jan, Goffin, Frederic, Haidopoulos, Dimitrios, Haller, Herman, Jach, Robert, Yezhova, Iryna, Berlev, Igor, Bernardino, Margarida, Bharathan, Rasiah, Lanner, Maximilian, Maenpaa, Minna M, Sukhin, Vladyslav, Feron, Jean-Guillaume, Fruscio, Robert, Kukk, Kersti, Ponce, Jordi, Abdalla, Nabil, Akbayir, Özgür, Akgöl, Sedat, Aksahin, Elif, Alonso-Espias, Maria, Aluloski, Igor, Andrade, Claudia, Badzakov, Nikola, Barrachina, Rosa, Bogani, Giorgio, Bonci, Eduard-Aexandru, Bonsang-Kitzis, Hélène, Brucker, Cosima, Cárdenas, Laura, Casajuana, Andrea, Cavalle, Pere, Cea, Jorge, Chiofalo, Benito, Cordeiro, Gloria, Coronado, Pluvio, Cuadra, Maria, Díez, Javier, Costa, Teresa Diniz da, Domingo, Santiago, Dostalek, Lukas, Demirkiran, Fuat, Erasun, Diego, Fehr, Mathias, Fernandez-Gonzalez, Sergi, Ferrero, Annamaria, Fidalgo, Soledad, Fiol, Gabriel, Galaal, Khadra, García, José, Gebauer, Gerhard, Ghezzi, Fabio, Gilabert, Juan, Gomes, Nana, Gonçalves, Elisabete, Gonzalez, Virginia, Grandjean, Frederic, Guijarro, Miriam, Guyon, Frédéric, Haesen, Jolien, Hernandez-Cortes, Gines, Herrero, Sofía, Pete, Imre, Kalogiannidis, Ioannis, Karaman, Erbil, Kavallaris, Andreas, Klasa, Lukasz, Kotsopoulos, Ioannis, Kovachev, Stefan, Leht, Meelis, Lekuona, Arantxa, Luyckx, Mathieu, Mallmann, Michael, Mancebo, Gemma, Mandic, Aljosa, Marina, Tiermes, Martin, Victor, Martín-Salamanca, María Belén, Martinez, Alejandra, Meili, Gesine, Mendinhos, Gustavo, Mereu, Liliana, Mitrovic, Milena, Morales, Sara, Moratalla, Enrique, Morillas, Bibiana, Myriokefalitaki, Eva, PakižImre, Maja, Petousis, Stamatios, Pirtea, Laurentiu, Povolotskaya, Natalia, Prader, Sonia, Quesada, Alfonso, Redecha, Mikuláš, Roldan, Fernando, Rolland, Philip, Saaron, Reeli, Sarac, Cosmin-Paul, Scharf, Jens-Peter, Smrkolj, Špela, Sousa, Rita, Stepanyan, Artem, Študent, Vladimír, Tauste, Carmen, Trum, Hans, Turan, Taner, Undurraga, Manuela, Uppin, Arno, Vázquez, Alicia, Vergote, Ignace, Vorgias, George, Zapardiel, Ignacio, and Campillo, Francisco
- Published
- 2024
- Full Text
- View/download PDF
3. Prognostic factors in patients with uterine sarcoma: the SARCUT study
- Author
-
Zapardiel, Ignacio, Gracia Segovia, Myriam, Macuks, Ronalds, Mancari, Rosanna, Achimas-Cadariu, Patriciu, Corrado, Giacomo, Bartusevicius, Arnoldas, Sukhin, Vladyslav, Muruzabal, Juan C, Coronado Martín, Pluvio J, Gardella, Barbara, Piek, Jurgen M, Concin, Nicole, Arab, Clemente, Papatheodorou, Dimitrios, Polterauer, Stephan, Iacoponi, Sara, Nieto, Teresa, Lopez-Sanclemente, Martha C, Trukhan, Hanna, Gil, Maria M, Bakinovskaya, Irina, Dalamanava, Alena, Cucurull, Marc, Rovski, Dzmitry, Baquedano, Laura, Chiva, Luis, Mardas, Marcin, Mavrichev, Siarhei Anatolievich, Klat, Jaroslav, Lopez de la Manzanara, Carlos A, and Yildirim, Yusuf
- Published
- 2023
- Full Text
- View/download PDF
4. SUCCOR quality: validation of ESGO quality indicators for surgical treatment of cervical cancer
- Author
-
Boria, Felix, Chiva, Luis, Chacon, Enrique, Zanagnolo, Vanna, Fagotti, Anna, Kucukmetin, Ali, Mom, Constantijne, Chakalova, Galina, Shamistan, Aliyev, Malzoni, Mario, Narducci, Fabrice, Arencibia, Octavio, Raspagliesi, Francesco, Toptas, Tayfun, Cibula, David, Kaidarova, Dilyara, Meydanli, Mehmet Mutlu, Tavares, Mariana, Golub, Dmytro, Perrone, Anna Myriam, Poka, Robert, Zusterzeel, Petra L M, Aluloski, Igor, Goffin, Frederic, Haidopoulos, Dimitrios, Haller, Herman, Jach, Robert, Yezhova, Iryna, Bernardino, Margarida, Bharathan, Rasiah, Maenpaa, Minna M, Sukhin, Vladyslav, Feron, Jean-Guillaume, Fruscio, Robert, Kukk, Kersti, Ponce, Jordi, Demirkiran, Fuat, Vorgias, George, Povolotskaya, Natalia, Coronado Martín, Pluvio J, Marina, Tiermes, Zapardiel, Ignacio, Bizzarri, Nicolò, Gorostidi, Mikel, Gutierrez, Monica, Manzour, Nabil, Berasaluce, Arantxa, and Martin-Calvo, Nerea
- Published
- 2022
- Full Text
- View/download PDF
5. SUCCOR cone study: conization before radical hysterectomy
- Author
-
Chacon, Enrique, Manzour, Nabil, Zanagnolo, Vanna, Querleu, Denis, Núñez-Córdoba, Jorge M, Martin-Calvo, Nerea, Căpîlna, Mihai Emil, Fagotti, Anna, Kucukmetin, Ali, Mom, Constantijne, Chakalova, Galina, Shamistan, Aliyev, Gil Moreno, Antonio, Malzoni, Mario, Narducci, Fabrice, Arencibia, Octavio, Raspagliesi, Francesco, Toptas, Tayfun, Cibula, David, Kaidarova, Dilyara, Meydanli, Mehmet Mutlu, Tavares, Mariana, Golub, Dmytro, Perrone, Anna Myriam, Poka, Robert, Tsolakidis, Dimitrios, Vujić, Goran, Jedryka, Marcin A, Zusterzeel, Petra L M, Beltman, Jogchum Jan, Goffin, Frederic, Haidopoulos, Dimitrios, Haller, Herman, Jach, Robert, Yezhova, Iryna, Berlev, Igor, Bernardino, Margarida, Bharathan, Rasiah, Lanner, Maximilian, Maenpaa, Minna M, Sukhin, Vladyslav, Feron, Jean-Guillaume, Fruscio, Robert, Kukk, Kersti, Ponce, Jordi, Minguez, Jose Angel, Vázquez-Vicente, Daniel, Castellanos, Teresa, Boria, Felix, Alcazar, Juan Luis, Chiva, Luis, Abdalla, Nabil, Akgöl, Sedat, Aksahin, Demirkiran, Aliyev, Shamistan, Alonso-Espias, Maria, Aluloski, Igor, Andrade, Claudia, Badzakov, Nikola, Barrachina, Rosa, Bogani, Giorgio, Bonci, Eduard-Aexandru, Bonsang-Kitzis, Hélène, Brucker, Cosima, Cárdenas, Laura, Casajuana, Andrea, Cavalle, Pere, Cea, Jorge, Chiofalo, Benito, Cordeiro, Gloria, Coronado, Pluvio, Cuadra, Maria, Díez, Javier, Costa, Teresa Diniz da, Domingo, Santiago, Dostalek, Lukas, Elif, Fuat, Erasun, Diego, Fehr, Mathias, Fernandez-Gonzalez, Sergi, Ferrero, Annamaria, Fidalgo, Soledad, Fiol, Gabriel, Galaal, Khadra, García, José, Gebauer, Gerhard, Ghezzi, Fabio, Gilabert, Juan, Gomes, Nana, Gonçalves, Elisabete, Gonzalez, Virginia, Grandjean, Frederic, Guijarro, Miriam, Guyon, Frédéric, Haesen, Jolien, Hernandez-Cortes, Gines, Herrero, Sofía, Pete, Imre, Kalogiannidis, Ioannis, Karaman, Erbil, Kavallaris, Andreas, Klasa, Lukasz, Kotsopoulos, Ioannis, Kovachev, Stefan, Leht, Uppin Arno, Lekuona, Arantxa, Luyckx, Mathieu, Mallmann, Michael, Mancebo, Gemma, Mandic, Aljosa, Marina, Tiermes, Martin, Victor, Martín-Salamanca, María Belén, Lago, Víctor, Martinez, Alejandra, Meili, Gesine, Mendinhos, Gustavo, Mereu, Liliana, Mitrovic, Milena, Morales, Sara, Moratalla, Enrique, Gómez-Hidalgo, Natalia R, Morillas, Bibiana, Myriokefalitaki, Eva, PakižImre, Maja, Petousis, Stamatios, Pirtea, Laurentiu, Povolotskaya, Natalia, Prader, Sonia, Quesada, Alfonso, Redecha, Mikuláš, Roldan, Fernando, Rolland, Philip, Saaron, Reeli, Sarac, Cosmin-Paul, Scharf, Jens-Peter, Smrkolj, Špela, Sousa, Rita, Stepanyan, Artem, Študent, Vladimír, Tauste, Carmen, Trum, Hans, Turan, Taner, Undurraga, Manuela, Vázquez, Alicia, Vergote, Ignace, Vorgias, George, and Zapardiel, Ignacio
- Published
- 2022
- Full Text
- View/download PDF
6. Radical hysterectomy in early cervical cancer in Europe: characteristics, outcomes and evaluation of ESGO quality indicators
- Author
-
Boria, Felix, Chiva, Luis, Zanagnolo, Vanna, Querleu, Denis, Martin-Calvo, Nerea, Căpîlna, Mihai Emil, Fagotti, Anna, Kucukmetin, Ali, Mom, Constantijne, Chakalova, Galina, Shamistan, Aliyev, Malzoni, Mario, Narducci, Fabrice, Arencibia, Octavio, Raspagliesi, Francesco, Toptas, Tayfun, Cibula, David, Kaidarova, Dilyara, Meydanli, Mehmet Mutlu, Tavares, Mariana, Golub, Dmytro, Perrone, Anna Myriam, Poka, Robert, Tsolakidis, Dimitrios, Vujić, Goran, Jedryka, Marcin A, Zusterzeel, Petra L M, Beltman, Jogchum Jan, Goffin, Frederic, Haidopoulos, Dimitrios, Haller, Herman, Jach, Robert, Yezhova, Iryna, Berlev, Igor, Bernardino, Margarida, Bharathan, Rasiah, Lanner, Maximilian, Maenpaa, Minna M, Sukhin, Vladyslav, Feron, Jean-Guillaume, Fruscio, Robert, Kukk, Kersti, Ponce, Jordi, Alonso-Espías, María, Minguez, Jose Angel, Vázquez-Vicente, Daniel, Manzour, Nabil, Jurado, Matias, Castellanos, Teresa, Chacon, Enrique, and Alcazar, Juan Luis
- Published
- 2021
- Full Text
- View/download PDF
7. Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee
- Author
-
Kurtz, Jean-Emmanuel, Gebski, Val, Sukhin, Vladyslav, Carey, Mark, Kong, Iwa, Glasspool, Rosalind M., Berek, Jonathan S., de Paiva Batista, Mariana, Hall, Marcia, Kim, Jae-Weon, Yeoshoua, Effi, Fujiwara, Noriko, Nam, Byung-Ho, Polleis, Sandra, Lee, Jung-Yun, Strojna, Aleksandra, Farrelly, Laura, Schwameis, Richard, Fossati, Roldano, Darlington, Anne-Sophie, Lai, Chyong-Huey, Wright, Alexi A., Rosenblat, Orgad, Harter, Phillip, Roxburgh, Patricia, Chowdhury, Rahul Roy, Chang, Ting-Chang, Paoletti, Xavier, and Friedlander, Michael
- Published
- 2021
- Full Text
- View/download PDF
8. Subspecialty training in Europe: a report by the European Network of Young Gynaecological Oncologists
- Author
-
Lanner, Maximilian, Nikolova, Tanja, Gutic, Bojana, Nikolova, Natasha, Pletnev, Andrei, Selcuk, Ilker, Vlachos, Dimitrios-Efthymios, Razumova, Zoia, Bizzarri, Nicolò, Theofanakis, Charlampos, Lepka, Piotr, Kahramanoglu, Ilker, Han, Sileny, Nasser, Sara, Molnar, Szabolcs, Hudry, Delphine, Montero-Macías, Rosa, de Lange, Natascha, Macuks, Ronalds, Hasanov, Mir Fuad, Karimbayli, Ramina, Gagua, Irina, Andrade, Claudia, Pardal, Catarina, Dotlic, Jelena, Alvarez, Rosa Maria, Hruda, Martin, Fruhauf, Filip, Ekdahl, Linnea, Antonsen, Sofie Leisby, Sukhin, Vladyslav, Eriksson, Ane Gerda Zahl, Gliozheni, Elko, Delic, Ratko, Satanova, Alima, Kovacevic, Nina, Gristsenko, Liidia, Babloyan, Suzanna, Zalewski, Kamil, and Bharathan, Rasiah
- Published
- 2021
- Full Text
- View/download PDF
9. Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
- Author
-
Auranen, Annika, Powell, Matthew A., Sukhin, Vladyslav, Landrum, Lisa M., Ronzino, Graziana, Buscema, Joseph, Bauerschlag, Dirk, Lalisang, Roy, Bender, David, Gilbert, Lucy, Armstrong, Amy, Safra, Tamar, Nevadunsky, Nicole, Sebastianelli, Alexandra, Slomovitz, Brian, Ring, Kari, Coleman, Robert, Podzielinski, Iwona, Stuckey, Ashley, and Teneriello, Michael
- Abstract
Background: In Part 1 of the phase III RUBY trial (NCT03981796) in patients with primary advanced or recurrent endometrial cancer (EC), dostarlimab plus carboplatin–paclitaxel (CP) significantly improved progression-free survival and overall survival compared with CP alone. Limited safety data have been reported for the combination of immunotherapies plus chemotherapy in this setting. Objectives: The objective of this analysis was to identify the occurrence of treatment-related adverse events (TRAEs) and immune-related adverse events (irAEs) and to describe irAE management in Part 1 of the RUBY trial. Design: RUBY is a phase III, randomized, double-blind, multicenter study of dostarlimab plus CP compared with CP alone in patients with primary advanced or recurrent EC. Methods: Patients were randomized 1:1 to dostarlimab 500 mg, or placebo, plus CP every 3 weeks for 6 cycles, followed by dostarlimab 1000 mg, or placebo, every 6 weeks for up to 3 years. Adverse events (AEs) were assessed according to Common Terminology Criteria for Adverse Events, version 4.03. Results: The safety population included 487 patients who received ⩾1 dose of treatment (241 dostarlimab plus CP; 246 placebo plus CP). Treatment-emergent AEs were experienced by 100% of patients in both arms. TRAEs occurred in 97.9% of the dostarlimab arm and 98.8% of the placebo arm. The most common TRAEs occurred at similar rates between arms and were mostly low grade. IrAEs occurred in 58.5% of patients in the dostarlimab arm and 37.0% of patients in the placebo arm. Dostarlimab- or placebo-related irAEs were reported in 40.7% of patients in the dostarlimab arm and 16.3% of the placebo arm. Conclusion: The safety profile of dostarlimab plus CP was generally consistent with that of the individual components. Dostarlimab plus CP has a favorable benefit–risk profile and is a new standard of care for patients with primary advanced or recurrent EC. Trial registration: NCT03981796. Plain language summary: Safety of dostarlimab plus carboplatin-paclitaxel compared with carboplatin-paclitaxel in primary advanced or recurrent endometrial cancer For many years, patients with primary advanced or recurrent endometrial cancer were treated with chemotherapy, specifically with a combination of carboplatin and paclitaxel. Recently, new treatments called immune checkpoint inhibitors have been used to treat endometrial cancer. Dostarlimab, an immune checkpoint inhibitor, is being tested to treat many types of cancer, including endometrial cancer. In the RUBY trial, a combination of dostarlimab plus chemotherapy was compared with chemotherapy alone as treatment for primary advanced or recurrent endometrial cancer. Results showed that patients treated with dostarlimab plus chemotherapy had a lower risk of their cancer becoming worse and a lower risk of dying. Results in this article describe the safety of dostarlimab plus chemotherapy compared with chemotherapy alone. All patients in the RUBY trial experienced at least one adverse event (an undesired effect that happens while receiving treatment or shortly after stopping treatment); most were determined to be caused by the cancer treatments. No differences in the frequency of the overall cancer treatment-related adverse events were seen in patients who received dostarlimab plus chemotherapy compared with those patients who received chemotherapy alone. Some patients experienced an immune-related adverse event. These are a specific type of undesired effect that can occur when patients are treated with immune checkpoint inhibitors. Immune-related adverse events occurred more frequently in patients who received dostarlimab plus chemotherapy than in those who received chemotherapy alone. Physicians were generally able to treat the immune-related adverse events, and only a low percentage of patients discontinued treatment because they experienced an immune-related adverse event. The types of adverse events seen were similar to a combination of those seen in patients who received dostarlimab alone or patients who received chemotherapy alone as treatment for endometrial cancer. Dostarlimab plus chemotherapy is a new standard of care for patients with primary advanced or recurrent endometrial cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. SUCCOR study: an international European cohort observational study comparing minimally invasive surgery versus open abdominal radical hysterectomy in patients with stage IB1 cervical cancer
- Author
-
Abdalla, Nabil, Akbayir, Özgür, Akgöl, Sedat, Aksahin, Elif, Aliyev, Shamistan, Alonso-Espias, Maria, Aluloski, Igor, Andrade, Claudia, Badzakov, Nikola, Barrachina, Rosa, Bogani, Giorgio, Bonci, Eduard-Aexandru, Bonsang-Kitzis, Hélène, Boria, Felix, Brucker, Cosima, Cárdenas, Laura, Casajuana, Andrea, Cavalle, Pere, Cea, Jorge, Chiofalo, Benito, Cordeiro, Gloria, Coronado, Pluvio, Cuadra, Maria, Díez, Javier, Costa, Teresa Diniz da, Domingo, Santiago, Dostalek, Lukas, Demirkiran, Fuat, Erasun, Diego, Fehr, Mathias, Fernandez-Gonzalez, Sergi, Ferrero, Annamaria, Fidalgo, Soledad, Fiol, Gabriel, Galaal, Khadra, García, José, Gebauer, Gerhard, Ghezzi, Fabio, Gilabert, Juan, Gomes, Nana, Gonçalves, Elisabete, Gonzalez, Virginia, Grandjean, Frederic, Guijarro, Miriam, Guyon, Frédéric, Haesen, Jolien, Hernandez-Cortes, Gines, Herrero, Sofía, Pete, Imre, Kalogiannidis, Ioannis, Karaman, Erbil, Kavallaris, Andreas, Klasa, Lukasz, Kotsopoulos, Ioannis, Kovachev, Stefan, Leht, Meelis, Lekuona, Arantxa, Luyckx, Mathieu, Mallmann, Michael, Mancebo, Gemma, Mandic, Aljosa, Manzour, Nabil, Marina, Tiermes, Martin, Victor, Martín-Salamanca, María Belén, Martinez, Alejandra, Meili, Gesine, Mendinhos, Gustavo, Mereu, Liliana, Mitrovic, Milena, Morales, Sara, Moratalla, Enrique, Morillas, Bibiana, Myriokefalitaki, Eva, PakižImre, Maja, ImrePete, Stamatios Petousis, Pirtea, Laurentiu, Povolotskaya, Natalia, Prader, Sonia, Quesada, Alfonso, Redecha, Mikuláš, Roldan, Fernando, Rolland, Philip, Saaron, Reeli, Sarac, Cosmin-Paul, Scharf, Jens-Peter, Smrkolj, Špela, Sousa, Rita, Stepanyan, Artem, Študent, Vladimír, Tauste, Carmen, Trum, Hans, Turan, Taner, Undurraga, Manuela, Uppin, Arno, Vázquez, Alicia, Vergote, Ignace, Vorgias, George, Zapardiel, Ignacio, Chiva, Luis, Zanagnolo, Vanna, Querleu, Denis, Martin-Calvo, Nerea, Arévalo-Serrano, Juan, Căpîlna, Mihai Emil, Fagotti, Anna, Kucukmetin, Ali, Mom, Constantijne, Chakalova, Galina, Malzoni, Mario, Narducci, Fabrice, Arencibia, Octavio, Raspagliesi, Francesco, Toptas, Tayfun, Cibula, David, Kaidarova, Dilyara, Meydanli, Mehmet Mutlu, Tavares, Mariana, Golub, Dmytro, Perrone, Anna Myriam, Poka, Robert, Tsolakidis, Dimitrios, Vujić, Goran, Jedryka, Marcin A, Zusterzeel, Petra L M, Beltman, Jogchum Jan, Goffin, Frederic, Haidopoulos, Dimitrios, Haller, Herman, Jach, Robert, Yezhova, Iryna, Berlev, Igor, Bernardino, Margarida, Bharathan, Rasiah, Lanner, Maximilian, Maenpaa, Minna M, Sukhin, Vladyslav, Feron, Jean-Guillaume, Fruscio, Robert, Kukk, Kersti, Ponce, Jordi, Minguez, Jose Angel, Vázquez-Vicente, Daniel, Castellanos, Teresa, Chacon, Enrique, and Alcazar, Juan Luis
- Published
- 2020
- Full Text
- View/download PDF
11. SUCCOR study: an international European cohort observational study comparing minimally invasive surgery versus open abdominal radical hysterectomy in patients with stage IB1 cervical cancer
- Author
-
Chiva, Luis, Zanagnolo, Vanna, Querleu, Denis, Martin-Calvo, Nerea, Arévalo-Serrano, Juan, Căpîlna, Mihai Emil, Fagotti, Anna, Kucukmetin, Ali, Mom, Constantijne, Chakalova, Galina, Aliyev, Shamistan, Malzoni, Mario, Narducci, Fabrice, Arencibia, Octavio, Raspagliesi, Francesco, Toptas, Tayfun, Cibula, David, Kaidarova, Dilyara, Meydanli, Mehmet Mutlu, Tavares, Mariana, Golub, Dmytro, Perrone, Anna Myriam, Poka, Robert, Tsolakidis, Dimitrios, Vujić, Goran, Jedryka, Marcin A, Zusterzeel, Petra L M, Beltman, Jogchum Jan, Goffin, Frederic, Haidopoulos, Dimitrios, Haller, Herman, Jach, Robert, Yezhova, Iryna, Berlev, Igor, Bernardino, Margarida, Bharathan, Rasiah, Lanner, Maximilian, Maenpaa, Minna M, Sukhin, Vladyslav, Feron, Jean-Guillaume, Fruscio, Robert, Kukk, Kersti, Ponce, Jordi, Minguez, Jose Angel, Vázquez-Vicente, Daniel, Castellanos, Teresa, Chacon, Enrique, and Alcazar, Juan Luis
- Published
- 2020
- Full Text
- View/download PDF
12. SATEN III—Splitting Adjuvant Treatment of stage III ENdometrial cancers: an international, multicenter study
- Author
-
Kahramanoglu, Ilker, Meydanli, Mehmet Mutlu, Taranenka, Siarhei, Ayhan, Ali, Salman, Coskun, Sanci, Muzaffer, Demirkiran, Fuat, Ortac, Firat, Haidopoulos, Dimitrios, Sukhin, Vladyslav, Kaidarova, Dilyara, Stepanyan, Artem, Farazaneh, Farah, Aliyev, Shamistan, Ulrikh, Elena, Kurdiani, Dina, Yalcin, İbrahim, Mavrichev, Siarhei, Akilli, Huseyin, Sarı, Mustafa Erkan, Pletnev, Andrei, Aslan, Koray, Bese, Tugan, Kairbayev, Murat, Vlachos, Dimitrios, and Gultekin, Murat
- Published
- 2019
- Full Text
- View/download PDF
13. Patient-reported outcomes from the phase III, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 Study of pembrolizumab plus concurrent chemoradiotherapy among patients with high-risk, locally advanced cervical cancer.
- Author
-
Randall, Leslie, Sukhin, Vladyslav, Colombo, Nicoletta, Korach, Jacob, Matsumoto, Takashi, Lalondrelle, Susan, Vizkeleti, Julia, Samouelian, Vanessa, Salani, Ritu, Salman, Pamela, Nogueira-Rodrigues, Angelica, Ayhan, Ali, Frentzas, Sophia, Cueva, Juan, Kim, Yong-Man, Petru, Edgar, Milla, Dency Pilar, Sehouli, Jalid, Saevets, Valeriya, and Yamada, Karin
- Subjects
- *
PATIENT reported outcome measures , *CERVICAL cancer , *CHEMORADIOTHERAPY , *PEMBROLIZUMAB - Published
- 2024
- Full Text
- View/download PDF
14. EVALUATION OF HORMONAL FUNCTION IN WOMEN WITH CERVICAL INSUFFICIENCY AND INFERTILITY IN THE HISTORY.
- Author
-
Perkhulyn, Oksana M., Pakharenko, Lyudmyla V., Sukhin, Vladyslav S., Saltovskiy, Oleksiy V., Kovalchuk, Viktoriia M., Hranovska, Hanna I., and Kravchenko, Olha V.
- Published
- 2021
- Full Text
- View/download PDF
15. Patient-reported Outcomes in Patients With Primary Advanced or Recurrent Endometrial Cancer Who Received Dostarlimab Plus Carboplatin-Paclitaxel vs Carboplatin-Paclitaxel in the ENGOT-EN6/GOG3031/RUBY Trial.
- Author
-
Mirza, Mansoor Raza, Powell, Matthew A., Lundgren, Caroline, Sukhin, Vladyslav, and Pothuri, Bhavana
- Subjects
THERAPEUTIC use of monoclonal antibodies ,THERAPEUTIC use of antineoplastic agents ,CARBOPLATIN ,HEALTH outcome assessment ,CANCER relapse ,CONFERENCES & conventions ,CANCER patients ,ENDOMETRIAL tumors ,PACLITAXEL - Abstract
Background: RUBY (NCT03981796) is a phase 3, randomized, placebo-controlled trial in patients with primary advanced or recurrent endometrial cancer (pA/rEC). In RUBY, dostarlimab plus carboplatin-paclitaxel (D+CP) demonstrated clinically meaningful efficacy in patients with pA/rEC, including a significant improvement in progression-free survival (PFS), compared with placebo (PBO) plus carboplatin-paclitaxel (PBO+CP).1 Objective: To examine and report similarities and differences in patient-reported outcomes (PROs) in patients with pA/rEC who received either D+CP or PBO+CP in the phase 3 RUBY trial. Methods: A total of 494 patients with pA/rEC were randomized 1:1 to receive either D+CP or PBO+CP every 3 weeks for 6 cycles, followed by D or PBO alone every 6 weeks for up to 3 years or until disease progression. As a secondary endpoint, PRO questionnaires for patients with any cancer (ie, the European Organisation for Research and Treatment of Cancer [EORTC] QLQ-C30) and for patients with endometrial cancer (ie, EORTC QLQ-EN24) were administered on day 1 of each treatment cycle (C), at end of treatment, and at safety and survival follow-up points. Changes in patients' scores over time were calculated using mixed model for repeated measures analyses, and least-squares means (LSMs) were used to quantify the difference between treatment arms in change observed in patients' scores over time. Results are reported here for C7 (the end of chemotherapy) and C13 (the end of 1 year of study follow-up). Results: PRO scores were similar in patients who received D+CP and PBO+CP through the chemotherapy period (C7). After 1 year of study follow-up (C13), the mean change in global health status/quality-of-life (GHS/QoL) score from baseline was 3.3 (SD, 23.51) with D+CP, and -0.9 (SD, 19.25) with PBO+CP (positive score indicates improvement; ≥10-point change was considered clinically meaningful). Over the 3-year study period, no differences between the 2 treatment arms were detected (P≥.05 indicated no significant difference) based on LSMs; more specifically, GHS/QoL was 0.5 (P=.72), physical function was -0.7 (P=.63), fatigue was 0.2 (P=.91), and pain was -1.0 (P=.62). At the end of study treatment, patients who received D+CP reported improvement in back/pelvic pain compared with baseline; patients receiving PBO+CP reported worsening of GHS/QoL, social functioning, body image, and change in taste compared with baseline. Conclusions: In this study, patients with pA/rEC receiving D+CP experienced significantly improved PFS while maintaining health-related QoL. These findings further support the use of D+CP as a standard of care in treating patients with pA/rEC. Funding: This study was sponsored by GSK. Editorial support provided by ArticulateScience, LLC, and funded by GSK. [ABSTRACT FROM AUTHOR]
- Published
- 2023
16. Patient-reported outcomes (PROs) in primary advanced or recurrent endometrial cancer (pA/rEC) for patients (pts) treated with dostarlimab plus carboplatin/paclitaxel (CP) as compared to CP in the ENGOT-EN6/GOG3031/RUBY trial.
- Author
-
Mirza, Mansoor Raza, Powell, Matthew A., Lundgren, Caroline, Sukhin, Vladyslav, Pothuri, Bhavana, Gilbert, Lucy, Gill, Sarah, Ronzino, Graziana, Nevadunsky, Nicole, Kommoss, Stefan, Willmott, Lyndsay, Boere, Ingrid, Mathews, Cara Amanda, Buscema, Joseph, Teneriello, Michael, Shahin, Mark S., Meyers, Oren, Garside, Jamie, Coleman, Robert L., and Slomovitz, Brian M.
- Published
- 2023
- Full Text
- View/download PDF
17. Assessment of palliative care training in gynaecological oncology: a survey among European Network of Young Gynae-Oncologists (ENYGO) members.
- Author
-
La Russa M, Zapardiel I, Zalewski K, Laky R, Dursun P, Sukhin V, Lindquist D, and Lindemann K
- Subjects
- Humans, Europe, Female, Gynecology education, Surveys and Questionnaires, Adult, Male, Genital Neoplasms, Female therapy, Terminal Care, Curriculum, Attitude of Health Personnel, Middle Aged, Palliative Care, Medical Oncology education
- Abstract
Introduction: Palliative care is an important aspect of gynaecological oncology practice. In order to successfully integrate end-of-life (EOL) care in the disease trajectory, it is crucial to incorporate systematic training in subspecialty programmes in gynaecological oncology. We aimed to evaluate the quality of training in palliative care across gynaecological oncology fellows in Europe and to provide a framework to facilitate learning opportunities., Methods: A web-based questionnaire was sent to members of the European Network of Young Gynae-Oncologists (ENYGO). The survey consisted of 36 items covering six domains: respondents' characteristics, quality and quantity of teaching, curriculum achievements, observation and feedback, EOL clinical practice and attitudes about palliative care., Results: Of the 703 clinicians enrolled in the study, 142 responded (20.2%). Although the majority worked in university hospitals, only half of them (47%) were in a formal subspecialty programme. The majority of respondents (60%) were trained without a mandatory rotation in palliative care units and considered the quality of EOL care teaching as 'very poor' or 'poor' (57.7%). The majority of respondents (71.6%) did not receive any supervision or feedback at the time of their first consultation on changing the goals of care., Conclusion: Our study underlines lack of structured teaching and supervision in palliative care contents among European fellows in gynaecological oncology. Broad education of healthcare providers is a key factor to achieve the integration of palliative care in gynaecological oncology practice. Stakeholders like European Society of Gynaecological Oncology/ENYGO play an important role to facilitate educational activities and training programmes targeting to EOL care., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2025. No commercial re-use. See rights and permissions. Published by BMJ Group.)
- Published
- 2024
- Full Text
- View/download PDF
18. Gynecologic oncology training systems in Europe: a report from the European network of young gynaecological oncologists.
- Author
-
Gultekin M, Dursun P, Vranes B, Laky R, Bossart M, Grabowski JP, Piek JM, Manchanda R, Grimm C, Dallaku K, Babloyan S, Moisei A, Van Gorp T, Cadron I, Markov P, Micevska A, Halaska M, Steffensen KD, Gristsenko L, Nissi R, Lambaudie E, Tsitsishvili Z, Haidopoulos D, Tsolakidis D, Novak Z, Peiretti M, Dunenova G, Macuks R, Hetland TE, Michelsen TM, Martins FC, Achimas-Cadariu P, Ulrikh EA, Uharcek P, Malic S, Ognjenovic D, Zapardiel I, Johann S, Sukhin VS, and Manchanda R
- Subjects
- Europe, Gynecology education, Medical Oncology education
- Abstract
Objective: The objectives of the study were to highlight some of the differences in training systems and opportunities for training in gynecologic oncology across Europe and to draw attention to steps that can be taken to improve training prospects and experiences of European trainees in gynecologic oncology., Methods: The European Network of Young Gynaecological Oncologists national representatives from 34 countries were asked to review and summarize the training system in their countries of origin and fulfill a mini-questionnaire evaluating different aspects of training. We report analysis of outcomes of the mini-questionnaire and subsequent discussion at the European Network of Young Gynaecological Oncologists national representatives Asian Pacific Organization for Cancer Prevention meeting in Istanbul (April 2010)., Results: Training fellowships in gynecologic oncology are offered by 18 countries (53%). The median duration of training is 2.5 years (interquartile range, 2.0-3.0 years). Chemotherapy administration is part of training in 70.5% (24/34) countries. Most of the countries (26/34) do not have a dedicated national gynecologic-oncology journal. All trainees reported some or good access to training in advanced laparoscopic surgical techniques, whereas 41% indicated no access, and 59% some access to training opportunities in robotic surgery. European countries were grouped into 3 different categories on the basis of available training opportunities in gynecologic oncology: well-structured, moderately structured, and loosely structured training systems., Conclusions: There is a need for further harmonization and standardization of training programs and structures in gynecologic oncology across Europe. This is of particular relevance for loosely structured countries that lag behind the moderately structured and well-structured ones.
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.